52-week rangeThe lowest and highest prices the stock traded at over the last year, from each day's intraday low and high. The marker is today's close: 0% means it sits at the year's low, 100% at the high. It describes where the price is, not where it is going.48.7% up the range
Rs 337Rs 447
What Biocon does
A short, human-reviewed summary of the business, written from public sources. Background, not analysis, and not updated intraday.
business summary
Biocon is not primarily a formulations company: its core business, run through subsidiary Biocon Biologics, makes biosimilars, near-copies of complex biologic drugs like insulin and cancer antibodies, a far harder regulatory path than ordinary generics. It also majority owns Syngene, itself a separately NSE-listed company that sells no drugs of its own and instead runs contract research and manufacturing for other pharma, biotech and agrochemical companies worldwide.
1
1Sector
Pharma - Biosimilars & Biologics
2
2What it sells
Biosimilar insulins and monoclonal antibodies used in diabetes, oncology and immunology, plus, through Syngene, contract research, development and manufacturing services for other companies' drug candidates.
3
3Who buys it
Health systems, hospitals and distributors in many countries buying its biosimilars as lower-cost alternatives to original biologic drugs, plus other pharma, biotech and agrochemical companies that pay Syngene to run research and manufacturing on their behalf.
4
4How it earns
Profits from being a cheaper, harder-to-copy alternative to expensive patented biologic drugs once their patents expire; the tough manufacturing and regulatory approval process is itself a barrier that protects margins once a biosimilar is approved. Profitability moves with new biosimilar approvals in the US and EU, insulin pricing, and Syngene's client research revenue.
Implied vs realized volatility
This compares the volatility options are pricing (from the chain) with the volatility the stock has actually delivered. It appears once the live options chain is available.
options live in market hours
The options-implied volatility comes from the live chain, which is available during and around market hours (9:15-3:30 IST, Mon-Fri). The stock has realized 19.2% volatility over the last 30 days; the implied figure and the comparison will show when the chain is live.
BIOCON price vs the biggest options level
The daily candles are the actual stock. The two labeled lines are the single strike with the most call open interest (a resistance level option sellers are defending) and the single strike with the most put open interest (a support level). The full breakdown across every strike is in the Open Interest Profile card below.
EOD 11 Sept
IndicatorsVolume
Loading BIOCON price...
Options snapshot
The live stock option chain (PCR, max pain, expected move, OI) loads during and around market hours.
live in market hours
BIOCON's live option chain - put-call ratio, max pain, expected move and open-interest walls - appears during market hours (9:15-3:30 IST, Mon-Fri). Come back when the market is open for the full options view.
Returns and valuation
Built from the company's own balance sheet and cash flow. Return on equity is the trailing twelve months of profit against the equity on the books; the balance sheet behind it is filed twice a year, not four times.
from the filing as at 2026-03-31
Market cap
Rs 63,660 Cr
what the whole company is priced at today
Return on equity
1.1%
profit earned on every Rs 100 of shareholders money
Price to book
1.87x
1.87 times the value on its own books
Return on assets
0.7%
profit against everything it owns
Return on capital
2.9%
EV / EBITDA
22.2x
Dividend yield
0.14%
paid out on today's price
Book value / share
Rs 209
the company's own books, per share
What it owns and what it owes
Straight from the balance sheet in the company's filing. Net debt is borrowings less cash and liquid investments, so a negative figure means it holds more cash than debt.
as at 2026-03-31
Total assets
Rs 63,651 Cr
everything the company owns
Shareholders equity
Rs 36,622 Cr
58% of what it owns is funded by its owners
Cash and equivalents
Rs 2,417 Cr
cash and near-cash on hand
Net debt
Rs 11,718 Cr
borrowings less cash
Debt to equity
0.40x
borrowings against the owners' money
Current ratio
1.22x
short-term assets against short-term dues
Companies file a balance sheet twice a year, not every quarter, so this is the most recent one published rather than the latest quarter.
The cash it actually made
Profit is an accounting figure; cash flow is what moved. Free cash flow is the cash from running the business less what was spent on plant and equipment, so it is what was left over to pay down debt or return to shareholders.
year to 2026-03-31
Cash from operations
Rs 1,994 Cr
cash the business itself threw off
Free cash flow
Rs 196 Cr
what was left after spending on the business
FCF margin
1.2%
free cash for every Rs 100 of sales
Cash vs profit
5.41x
every rupee of profit arrived as cash, or more
Cash flow is reported for the year to date, so this covers the full period ending 2026-03-31 rather than a single quarter.
Fundamentals
Trailing-twelve-month valuation, margins and growth from the company's own filings.
as of 2026-06-30
P/E (TTM)
115.6
PEG
2.17
EPS (TTM)
Rs 3.4
Net margin
2.4%
Rev growth YoY
+10.00%
Profit growth YoY
+53.36%
TTM revenue
Rs 17,321 Cr
TTM net profit
Rs 416 Cr
Against its sector
Where this stock sits within its own sector on each measure. The marker is its position in the peer group and the notch is the sector median. A position is a fact about the cohort, not a view on the stock.
Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.
The business
Sales and net profit from the company's own filings, by financial year or by quarter. Hover any bar for that period's complete figures including operating margin and the change against the comparable earlier period. The single TTM figure above is the sum of the last four quarters.
5 years · 20 quarters
Full financial years - the long arc of the business.
Sales growth
+14.8%
a year, 3 years
Profit growth
-16.9%
a year, 3 years
Operating margin
20.3%
latest year
Sales by financial yearRs 16,927 Cr
Net profit by financial yearRs 369 Cr
FY225 full years · hover a yearFY26
Operating margin has gone from 23.4% to 20.3% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.
Dividends paid
Cash paid per share, from the exchange's corporate-action record, restated to today's share count across bonuses and splits. Dates shown are ex-dates: you must own the shares before that date to receive the payment.
Rs 128 in 2025
Paid 5 of 10 yrs
what 2025's payouts come to on Rs 1 lakh at today's price · nothing declared in the last twelve months
What each year paid, on Rs 1 lakh
212
128
128
384
128
16
17
18
19
20
21
22
23
24
25
2025 paid Rs 0.50 per share, about Rs 128 on Rs 1 lakh at today's price. It skipped 5 of the last 10 years. Earlier years are restated to today's share count, so a bonus or split never reads as a dividend cut. Dividends are at the company's discretion and can be cut or skipped.
Technical snapshot
Momentum, trend and delivery-based conviction from the actual price and volume history.
EOD 11 Sept
RSI (14) - momentum
31.9Neutral
0 oversold3070overbought 100
Delivery % - genuine buying vs churn
44.1%Near average
today 44.1%20d avg 52.8%
The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
vs 50-DMA
-6.62%
vs 200-DMA
-1.28%
1-month
-6.99%
3-month
-6.73%
1-year
+7.41%
Realized vol (30d)
19.2%
Insider trading disclosures
Promoter, director and other insider trades in the company's own shares, as disclosed to the exchange under SEBI's insider-trading regulations - usually within a few days of the transaction.
last 18 months
Insider trading data unavailable.
Recent announcements
The company's own filings to the exchange - results, board meetings, investor calls - with a link to the source document.
last 6 months
Announcements unavailable.
Want to test a strategy on BIOCON?
Backtest an equity strategy on real market data, free - no card needed.
Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.